<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2019-08-01</periodOfReport>

    <dateOfOriginalSubmission>2019-08-05</dateOfOriginalSubmission>

    <issuer>
        <issuerCik>0001586049</issuerCik>
        <issuerName>Oxford Immunotec Global PLC</issuerName>
        <issuerTradingSymbol>OXFD</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001245055</rptOwnerCik>
            <rptOwnerName>SANDBERG RICHARD A</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O OXFORD IMMUNOTEC GLOBAL PLC</rptOwnerStreet1>
            <rptOwnerStreet2>94C INNOVATION DRIVE</rptOwnerStreet2>
            <rptOwnerCity>ABINGDON, OXFORDSHIRE</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>OX14 4RZ</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2019-08-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>3000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>12.90090</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017.</footnote>
        <footnote id="F2">The price reported for the sales on August 1, 2019 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $12.90 to $12.925 per share, inclusive.  The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.</footnote>
        <footnote id="F3">Price amended from the original filing made on 08/05/2019 which reflected a price of $19.9009 to the corrected price of $12.9009.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Matthew T E McLaughlin, as Attorney-in-Fact for Richard A. Sandberg</signatureName>
        <signatureDate>2019-08-05</signatureDate>
    </ownerSignature>
</ownershipDocument>
